SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.47
-0.21 (-0.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close42.68
Open42.60
Bid42.47 x 2200
Ask42.48 x 1000
Day's Range42.41 - 42.76
52 Week Range38.97 - 45.62
Volume2,957,006
Avg. Volume1,289,831
Market Cap105.394B
Beta (3Y Monthly)0.40
PE Ratio (TTM)21.89
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.74 (4.30%)
Ex-Dividend Date2019-05-07
1y Target Est52.00
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zacksyesterday

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

  • Does Sanofi (EPA:SAN) Create Value For Shareholders?
    Simply Wall St.2 days ago

    Does Sanofi (EPA:SAN) Create Value For Shareholders?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • Lilly Announces Tradjenta Cardiovascular Outcome Study Data
    Zacks4 days ago

    Lilly Announces Tradjenta Cardiovascular Outcome Study Data

    Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

  • CNW Group4 days ago

    Canadian employers underestimate the presence of chronic disease in the workforce

    TORONTO , June 11, 2019 /CNW Telbec/ - The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve to help guide decision-making among employers who provide health benefit plans to employees. A persistent gap is employers' underestimation of the presence of chronic disease in their workforce, which suggests they may also underestimate the negative impact of unmanaged disease on productivity.

  • Sanofi (SNY) in Focus: Stock Moves 5.5% Higher
    Zacks5 days ago

    Sanofi (SNY) in Focus: Stock Moves 5.5% Higher

    Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.

  • Benzinga8 days ago

    Sanofi's Leadership Transition: What You Need To Know

    With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth. Sanofi has a mandatory 65-year-old retirement age for its CEO.

  • New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
    InvestorPlace8 days ago

    New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

    There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.

  • Sanofi Taps Novartis Executive as CEO in Race for New Drugs
    Bloomberg8 days ago

    Sanofi Taps Novartis Executive as CEO in Race for New Drugs

    Bringing in Paul Hudson as its next chief executive officer will help the French pharma giant bolster its pipeline of medicines and deal with growing U.S. pressure on drug prices. The 51-year-old British executive will take over in September from Olivier Brandicourt, 63, who’s retiring. Hudson has led Novartis’s pharma unit since 2016 and is credited with launching key medicines such as psoriasis treatment Cosentyx, which may become its top product this year with a projected $3.5 billion in sales.

  • Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
    Zacks8 days ago

    Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

    Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

  • Novartis Appoints New Pharma Unit Head, Gives Other Updates
    Zacks8 days ago

    Novartis Appoints New Pharma Unit Head, Gives Other Updates

    Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

  • Benzinga8 days ago

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Reuters8 days ago

    UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO

    * Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 (Reuters) - Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest move by a Novartis executive to a competitor.

  • Reuters8 days ago

    UPDATE 1-European stocks head for best week in 2 months, Sanofi jumps

    European stocks were on course to notch their best weekly performance in two months on Friday as a jump in shares of French pharma giant Sanofi added to the positive mood created by expectations of more moves by central banks to stir growth. France's CAC 40 outperformed its peers with a 1.2% rise, helped by a 4.5% jump in Sanofi after the company appointed Swiss rival Novartis' executive Paul Hudson as its new boss.

  • Financial Times8 days ago

    Sanofi appoints top Novartis executive as new chief

    French drugmaker Sanofi has announced that a top executive from Swiss rival Novartis will succeed Olivier Brandicourt as CEO. Paul Hudson, who was most recently chief executive of the Novartis pharmaceuticals business and member of the executive committee of the overall group, will take over on September 1. since Sanofi’s diabetes treatments lost patent protection and came under pressure from cheaper rivals.

  • Reuters8 days ago

    European stocks recover after ECB disappointment

    European stocks were in recovery mode on Friday after a cautious message from the European Central Bank hit investors' appetite for risk in the previous session, with traders eyeing a U.S. jobs report and U.S. trade tussles with Mexico for fresh direction. Automakers climbed on a report that U.S. President Donald Trump could delay the tariffs he had threatened to put on Mexican goods as soon as this coming Monday, while French drugmaker Sanofi gained on its appointment of a new chief executive. France's CAC 40 outperformed its euro-peers with a 0.9%, helped by French pharma giant Sanofi.

  • Reuters8 days ago

    CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO

    Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday. Hudson will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest transfer of a Novartis executive to a competitor. UK-born Hudson, 51, has been CEO of the Novartis Pharmaceuticals, one of the Swiss company's three main divisions, since 2016.

  • Reuters8 days ago

    Swiss drugmaker Novartis names new drug division head

  • Local biotech firm bought for up to $70M
    American City Business Journals9 days ago

    Local biotech firm bought for up to $70M

    CytoSen Therapeutics Inc., which creates anti-cancer cell treatments, was acquired for a stock transaction by Netherlands-based Kiadis Pharma NV that could be valued at up to $70 million, depending on stock prices throughout the deal.Kiadis will include an upfront consideration of 1.94 million shares of its stock as part of the deal. Kiadis shares were trading at $7.70 as of June 6, according to Yahoo!Finance, The acquisition, announced on April 17, comes as as both companies are working on cell-based technology that helps fight cancer naturally, CytoSen co-founder Robert Igarashi told Orlando Business Journal. "It's fair to say, Orlando is continuing to be an up-and-coming life sciences center.

  • Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
    Zacks9 days ago

    Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

    The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

  • Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
    Zacks10 days ago

    Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

    GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

  • Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
    Zacks11 days ago

    Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

    Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

  • Reuters11 days ago

    Sanofi loses German patent case against Amgen over cholesterol drug

    Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent. In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special licence that would have protected its Praluent business. Officials at Sanofi did not have an immediate comment.

  • Small-Cap Biotechs Aim to Steal Spotlight at Cancer Meeting
    Bloomberg15 days ago

    Small-Cap Biotechs Aim to Steal Spotlight at Cancer Meeting

    Companies like Iovance Biotherapeutics Inc., MacroGenics Inc. and Nektar Therapeutics will be in the spotlight when the annual event kicks off Friday in Chicago. “Sentiment heading into the conference is notably bland, but there should still be enough stock-specific events to keep us on our toes,” Baird analyst Brian Skorney said in a note to clients. The Nasdaq Biotechnology Index has fallen 12% from its March highs as investors lamented some high-profile drug failures and a lack of big deals.

  • Amarin Rises on Priority Review for Vascepa Label Expansion
    Zacks16 days ago

    Amarin Rises on Priority Review for Vascepa Label Expansion

    Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

  • BioMarin Announces Data on Hemophilia Candidate, Shares Fall
    Zacks17 days ago

    BioMarin Announces Data on Hemophilia Candidate, Shares Fall

    BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.